We have located links that may give you full text access.
Journal Article
Review
Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
Topics in Current Chemistry (Journal) 2017 April
Recently, co-delivery of siRNA and anticancer drugs has drawn much attention in the treatment of drug-resistant cancers. Drug resistance is exhibited by cancer cells, which limits the efficacy of chemotherapy. When siRNA and anticancer drugs are delivered into cancer cells simultaneously, the siRNA is expected to silence the genes related to drug resistance, decreasing the drug efflux pumps and activating the cell's apoptosis pathways. In a timeframe following the release of siRNA, the accumulation of the co-delivered anti-cancer drug inside of the cancer cells will increase, resulting in promoted chemotherapeutic effects. Several classes of nanocarriers have been designed based on polymers for co-delivery, including surface-modified polymer nanoparticles (NPs), polymer micelles, dendrimers, polymer nanocapsules, polymer-modified liposomes, and polymer-modified silica and gold NPs. Compared with separate delivery, co-delivery showed significant advantages in the treatment of drug-resistant cancers. This review focuses on polymers in the co-delivery of siRNA and anticancer drugs, and summarizes key advances in the recent several years.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app